{"DataElement":{"publicId":"5916920","version":"1","preferredName":"Follicular Lymphoma F2 Progression-free Survival Score","preferredDefinition":"Number or range of numbers that represents the Follicular Lymphoma International Prognostic Index 2 (FLIPI-2) score to predict progression-free survival.","longName":"F2_OS_SCR","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5916919","version":"1","preferredName":"Follicular Lymphoma Follicular Lymphoma International Prognostic Index 2 Progression-free Survival","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001)._A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors)._The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.","longName":"2676495v1.0:5916917v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2676495","version":"1","preferredName":"Follicular Lymphoma","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin's lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). -- 2003","longName":"C3209","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3939D50A-661F-43F5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-03","modifiedBy":"ONEDATA","dateModified":"2007-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5916917","version":"1","preferredName":"Follicular Lymphoma International Prognostic Index 2 Progression-free Survival","preferredDefinition":"A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).:The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.","longName":" C137658:C28234","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma International Prognostic Index 2","conceptCode":"Follicular Lymphoma Internatio","definition":"A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progression-free Survival","conceptCode":"C28234","definition":"The length of time during and after treatment in which a patient is living with a disease that does not get worse. Progression-free survival may be used in a clinical study or trial to help find out how well a new treatment works.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B63159-AC59-6D8B-E053-F662850A1419","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"ONEDATA","dateModified":"2017-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B63159-AC6A-6D8B-E053-F662850A1419","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"COOPERM","dateModified":"2017-08-04","changeDescription":"Created for 17C0127 requested 7/20/17 by Y.Yakovlev. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5916913","version":"1","preferredName":"Follicular Lymphoma International Prognostic Index 2 Score","preferredDefinition":"A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors)._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"FLIPI2_SCORE","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"3-5","valueDescription":"High Risk","ValueMeaning":{"publicId":"5916914","version":"1","preferredName":"High Risk","longName":"5916914","preferredDefinition":"A score indicating that a patient has 3-5 risk factors associated with follicular lymphoma and is considered in the high risk group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLIPI-2 Score 3-5, High Risk","conceptCode":"C137661","definition":"A score indicating that a patient has 3-5 risk factors associated with follicular lymphoma and is considered in the high risk group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-03CB-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55B62667-03E4-609D-E053-F662850AC7EB","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"ONEDATA","dateModified":"2017-08-01","deletedIndicator":"No"},{"value":"1-2","valueDescription":"Intermediate Risk","ValueMeaning":{"publicId":"5916915","version":"1","preferredName":"Intermediate Risk","longName":"5916915","preferredDefinition":"A score indicating that a patient has 1-2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLIPI-2 Score 1-2, Intermediate Risk","conceptCode":"C137660","definition":"A score indicating that a patient has 1-2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-03F0-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55B62667-0409-609D-E053-F662850AC7EB","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"ONEDATA","dateModified":"2017-08-01","deletedIndicator":"No"},{"value":"0","valueDescription":"Low Risk","ValueMeaning":{"publicId":"5916916","version":"1","preferredName":"Low Risk","longName":"5916916","preferredDefinition":"A score indicating that a patient has 0 risk factors associated with follicular lymphoma and is considered in the low risk group.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FLIPI-2 Score 0, Low Risk","conceptCode":"C137659","definition":"A score indicating that a patient has 0 risk factors associated with follicular lymphoma and is considered in the low risk group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-0415-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"55B62667-042E-609D-E053-F662850AC7EB","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"ONEDATA","dateModified":"2017-08-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5916912","version":"1","preferredName":"Follicular Lymphoma International Prognostic Index 2 Score","preferredDefinition":"A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).:A number or range of numeric values measuring performance, function, quality, or ability.","longName":" C137658:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma International Prognostic Index 2","conceptCode":"Follicular Lymphoma Internatio","definition":"A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (< 60 years or ≥ 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (< 12 g/dL or ≥ 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (< 6cm or ≥ 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-03A3-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"ONEDATA","dateModified":"2017-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B62667-03B4-609D-E053-F662850AC7EB","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"COOPERM","dateModified":"2017-08-04","changeDescription":"Created for 17C0127 requested 7/20/17 by Y.Yakovlev. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"F2 Score","type":"Preferred Question Text","description":"F2 Score","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"55B6501B-C964-6E50-E053-F662850AA5C9","latestVersionIndicator":"Yes","beginDate":"2017-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-08-01","modifiedBy":"COOPERM","dateModified":"2017-08-04","changeDescription":"Created for 17C0127 requested by Y.Yakovlev 7/20/17. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}